Sartorius Officially Opens Production Facility for Bioreactors in Guxhagen, Germany
News Sep 15, 2012
Sartorius has formally opened its new plant in Guxhagen in northern Hesse for the manufacture of bioreactors.
After approximately one year of construction, the new building was officially dedicated in the presence of the prime minister of the state government of Hesse, Volker Bouffier; the mayor of the community of Guxhagen, Edgar Slawik; as well as numerous guests from the local political and business community.
Approximately 18 million euros were invested in the plant at which Sartorius now manufactures bioreactors and further production equipment for customers in the biopharmaceutical industry.
Covering a total area of nearly 10,000 square feet, the new building complex provides space for a high-tech manufacturing hall and offices for around 240 employees.
The building owner is Robos GmbH, from which Sartorius has rented the premises in a long-term lease.
By opening this new site in Guxhagen, Sartorius has moved from its former bioreactor production facility in Melsungen, Germany, where it had reached maximum capacity limits.
Prime Minister Volker Bouffier stated after a tour of the plant, "By deciding to build a new production facility just a few kilometers away from Melsungen, Sartorius AG has reinforced its close ties with northern Hesse. At the same time, this decision also underscores the advantages of the business location of the State of Hesse, according to him: "We offer companies an excellent infrastructure and intentionally promote the regional economy so that innovative medium-sized companies will invest in and stay with us," said the Prime Minister.
"The new plant enables us to substantially enhance our manufacturing processes and creates additional capacity for us in view of the rising demand for biopharmaceutical production equipment. As a result, we are optimally prepared for further expansion, especially for single-use bioreactors," said Joachim Kreuzburg, the CEO and Executive Board Chairman of Sartorius AG.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE